One of the reasons we chose Genedata Biologics was the platform’s process coverage. We required that the full diversity of Pfizer’s large-molecule processes and technologies be supported by one integrated system.
Sergio Rotstein, Ph.D. Director of Research Business Technology
We chose Genedata Biologics because its built-in business logic avoids costly software customization and it’s a proven off-the-shelf-product that can be implemented quickly and replace our current processes.
We made a decision early on to use Genedata Biologics as MorphoSys’ workflow backbone to accelerate our drug discovery efforts and have watched as Genedata Biologics has become the global industry standard for biopharma discovery organizations.
Markus Enzelberger, Ph.D. Senior VP and Head of Discovery, Alliances and Technologies
Genedata Biologics will be our central repository for mission-critical data on therapeutic candidates such as bioactivity, developability, and manufacturability, and will enable transparent decision-making on candidates to move forward.
Bjoern Hock, Ph.D. Director, Global Head Protein Engineering and Antibody Technologies